Leadership

Marc Forth joined Jeune Aesthetics as President & CEO in April 2025. However, Mr. Forth’s has served as a valuable contributor on Jeune’s Board of Directors since February 2021. Mr. Forth has nearly 30 years of healthcare experience with a deep background in medical aesthetics, medical dermatology, neurosciences, urology and gynecology. He joins the company at a critical and exciting time, leading the transformation of Jeune into an independent, late-stage company focused on the development of truly innovative treatments designed to address the biology of aging skin.

Prior to Jeune Aesthetics, Mr. Forth spent nearly 6 years as the President & CEO of AEON Biopharma, Inc., a clinical stage, public company focused on the development of botulinum toxin designed to treat an array of nervous system-related conditions. Mr. Forth led the exclusive licensure for therapeutic use of ABP-450 in the U.S., Canada, Europe, Australia and other geographies from Daewoong Pharmaceutical Co., Ltd. and designed the corporate, development and regulatory strategies for ABP-450 in cervical dystonia, migraine and gastroparesis. Mr. Forth continues to serve on AEON Biopharma’s Board of Directors.

A veteran of the healthcare industry, Mr. Forth previously worked at Allergan PLC as the Senior Vice-President and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Divisions. During his 16-year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of neurosciences, urology and medical dermatology products, most notably Botox® for all therapeutic uses and, earlier in his career, led the commercial planning and execution for BOTOX® Cosmetic in the United States.

Mr. Forth started his career in healthcare at TAP Pharmaceuticals, holding numerous commercial roles for more than 7 years. Beginning as a Sales Representative, Mr. Forth gained experience in sales management, marketing, and payer marketing in urology, oncology, gynecology, and gastroenterology. Prior to TAP Pharmaceuticals, Mr. Forth worked at WSW Associates for 4 years, where he initially began his career as an Account Executive specializing in marketing, advertising, and public relations.

Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.

September Riharb is the Chief Marketing Officer at Jeune Aesthetics, Inc. Ms. Riharb is a senior executive with experience in public and private aesthetic companies. She was a key member of the Evolus management team where she helped lead the Company’s successful IPO and commercialization of the Company’s flagship neurotoxin product Jeuveau®. Ms. Riharb was the Sr. Director of Strategic Planning and later the VP of Development for Allergan. She was also one of the aesthetic market pioneers with McGhan Medical and INAMED. In addition to her aesthetic experience, Ms. Riharb launched first-wave disruptive technologies in minimally invasive surgery and medical robotics; she was instrumental in commercializing the first surgical robots and voice-activated operating rooms. Ms. Riharb holds a Bachelor of Arts from California State University, Fullerton.

Nishant Saxena brings extensive experience in life sciences, capital markets, and finance to his role as CFO at Jeune. Prior to joining Jeune, Mr. Saxena was a Managing Director in the strategic advisory practice focused on the biopharmaceutical sector at Evercore. In his over 15 years at Evercore, Mr. Saxena led numerous client engagements and advised on mergers and acquisitions, private placements, initial public offerings, follow-on offerings, partnerships, structured financings, and other transactions. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms. Mr. Saxena received a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.

Krish Krishnan is the Chairman and CEO at Krystal Biotech. He is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE:XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6 billion. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V:Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals,Inc. prior to its sale to Grunenthal GmbH in 2017. Previously, Krish served as a Managing Principal of Suppliermarket.com (a pharmaceutical B2B marketplace) that was sold to Ariba in 2001 for $500m. Krish started his career as a Senior Engineer at E.I.Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.

Suma Krishnan is the Founder and COO at Krystal Biotech. She has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE:XON). Previously, she led the discovery, development, and approval of Vyvanse (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.